Moderna (MRNA) Q3 Earnings and Revenues Top Estimates

Moderna (MRNA) posted Q3 earnings of $0.38 per share, crushing the consensus estimate of a $1.10 per share loss. That works out to a 134.55% earnings surprise, a swing from expected red ink to a profit.

Revenue came in at $1.31 billion, beating estimates by 47.73%. Both lines cleared the bar by wide margins, which is rare for a print where the Street was modeling a sizable loss.

The stock has already priced in plenty of good news. MRNA shares are up 718.8% year-to-date, against a 7.4% gain for the S&P 500. That is an enormous spread to the benchmark, and it frames how much of the story the market had absorbed before the report.

Zacks assigns MRNA a Rank #3 (Hold), which signals near-term performance in line with the broader market. Interpretation: the ranking suggests earnings-estimate revisions have not yet turned decisively bullish, even after this beat.